Eli Lilly (NYSE: LLY), the world’s largest healthcare company, is set to report its fourth-quarter and full-year 2025 earnings on February 4. Despite a history of strong returns, past earnings seasons have shown mixed results for the stock, with notable fluctuations following earnings updates. For instance, while the stock soared after strong third-quarter results, it declined despite positive second-quarter performance due to disappointing trial data for its GLP-1 candidate, orforglipron. Investors are now contemplating whether to purchase the stock ahead of the upcoming earnings report.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
